

11 October 2016

ASX Code: MXC

## Listed Options now Quoted – ASX Code: MXCOD

The Board of MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) would like to advise following the application for quotation of the Listed Options exercisable at \$0.065 expiring 30 June 2019 issued to eligible holders and announced on 6 October 2016, will be quoted from today under the ASX Code MXCOD.

For any queries in relation to this issue of new MXC securities quoted on the ASX, please contact the company directly on (08) 9389 2000 or [info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

-Ends-

**For further information, please contact:**

**Media Enquiries**

Andrew Ramadge  
Account Director  
Media and Capital Partners  
+61 475 797 471  
[andrew.ramadge@mcpartners.com.au](mailto:andrew.ramadge@mcpartners.com.au)

**MGC Pharmaceuticals Ltd**

Brett Mitchell  
Executive Chairman  
+61 8 9389 2000  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

**About MXC**

MGC Pharmaceuticals Ltd (ASX: MXC) is EU based specialist medical cannabis company with many years of technical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality non-psychoactive Cannabidiol (CBD) resin extract to the growing demand in cosmetics and medical markets in Europe, North America and Australasia. The Company is also developing strategic joint ventures in these key value add industries, as demonstrated with MGC Derma CBD cosmetics.